EFFICACY OF DNA AND PROTEIN CO-IMMUNIZATION PROTOCOL TO PROTECT MACAQUES FROM SHIV INFECTION
EFFICACY OF DNA AND PROTEIN CO-IMMUNIZATION PROTOCOL TO PROTECT MACAQUES FROM SHIV INFECTION
批准号:
9915806
负责人:
MARX PRESTON
金额:
$16.58万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-05 至 2019-10-31
关键词:
AIDS VaccinesAdvanced DevelopmentAntigensAwardClinicalComplementContractsDNADevelopmentDoseEvaluation StudiesFundingGrantHIVHIV vaccineHumoral ImmunitiesImmune responseImmunizationImmunotherapyIndividualInfectionIntravaginal AdministrationInvestigator-Initiated ResearchLocal MicrobicidesLongevityMacacaModalityMucous MembraneNational Institute of Allergy and Infectious DiseasePARP9 genePreventionPrevention strategyProteinsProtocols documentationRegimenResearch DesignResearch PersonnelResearch Project GrantsResourcesSIVVaccine ResearchVaccinesaluminum sulfateenv Gene Productsimprovednonhuman primatepre-clinicalpreclinical evaluationpreclinical studyprogramsprotective effectresponsesimian human immunodeficiency virusvaccine candidatevaccine deliveryvaccine developmentvaccine evaluation
中文摘要
艾滋病毒疫苗和其他预防战略的开发依赖于在临床前研究中使用非人类灵长类动物,以推进有效的艾滋病候选疫苗的开发,并推进有效的局部杀微生物剂和其他预防方式或基于免疫的疗法的开发。NIAID猿类疫苗评估单位(SVEU)合同将提供主要支持艾滋病疫苗临床前评估的非人类灵长类动物资源。SVEUs开展研究,以支持各种研究人员正在开发的疫苗。这些研究补充了niaid支持的基础疫苗研究和疫苗评估研究,这些研究由R01(研究者发起的研究)拨款、HIVRAD(艾滋病毒疫苗研究和设计计划)拨款、IPCAVD(临床前-临床综合艾滋病疫苗开发)拨款和NHP联盟资助。SVEUs还对公司或其他研究人员提供的候选疫苗进行研究。先前的研究调查了在猕猴中使用HIV或SIV gag和env免疫原的免疫方案,发现DNA+蛋白质共递送增加了对疫苗的全身和粘膜体液免疫反应的强度和寿命。这些研究发现,DNA+蛋白质共递送疫苗方案结合了每种疫苗成分的强度,并诱导了强大的细胞反应和持久的体液免疫。该方案改善幅度宽度,粘膜播散以及诱导免疫反应的保护作用。
英文摘要
The development of HIV vaccines and other prevention strategies relies on the use of nonhuman primates in preclinical studies to advance the development of effective AIDS vaccine candidates and to advance development of effective topical microbicides and other prevention modalities or immune-based therapies. The NIAID Simian Vaccine Evaluation Unit (SVEU) contracts shall provide nonhuman primate resources that primarily support preclinical evaluation of AIDS vaccines. The SVEUs conduct studies in support of vaccines being developed by a wide range of investigators. These studies complement NIAID-supported basic vaccine research and vaccine evaluation studies funded through R01 (investigator-initiated research) grants, HIVRAD (HIV Vaccine Research and Design Program) grants, IPCAVD (Integrated Preclinical-Clinical AIDS Vaccine Development) grants, and NHP Consortium awards. The SVEUs also perform studies of candidate vaccines offered by companies or other researchers. Previous studies investigating immunization regimens using HIV or SIV gag and env immunogens in macaques and have found that DNA+protein co-delivery increases the magnitude and longevity of systemic and mucosal humoral immune responses to vaccines. The studies have found that the DNA+protein co-delivery vaccine regimen combines the strength of each individual vaccine component and induces robust cellular responses as well as long-lasting humoral immunity. The regimen improves magnitude breadth, mucosal dissemination as well as protective effects of the induced immune responses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金